GoodCap Pharmaceuticals Inc.

Goodcap is developing psychedelic therapeutics for mood disorders, starting with post-traumatic stress disorder (PTSD). Their lead drug candidate combines psilocybin, a 5HT2a receptor agonist, and eugenol, a transient receptor potential (TRP) agonist, to mediate both chronic inflammation and oxidative stress, the root

Operating in health care, medical, therapeutics, wellness based in Great Lakes, GoodCap Pharmaceuticals Inc. was founded in 2021.

Profile

Goodcap is developing psychedelic therapeutics for mood disorders, starting with post-traumatic stress disorder (PTSD). Their lead drug candidate combines psilocybin, a 5HT2a receptor agonist, and eugenol, a transient receptor potential (TRP) agonist, to mediate both chronic inflammation and oxidative stress, the root causes of the symptomatology of PTSD. It provides PTSD patients with immediate relief […]

The company sits in the health care, medical, therapeutics, wellness segment, where it competes on its core product or service.

Great Lakes is where the company is located.

The company is listed at the Private company stage of development.

Its team size is recorded as c_00001_00010 employees.

Website: goodcap.com